Literature DB >> 7462439

Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time.

A D Heyns, D J van den Berg, P H Kleynhans, P W du Toit.   

Abstract

Activated partial thromboplastin times (APTT) for monitoring heparin therapy for venous thromboembolism tended to be inappropriately short if blood was collected in commercially available evacuated glass tubes. Five types of evacuated tubes marketed under the trade names Vacutainer and Venoject were examined. The APTT of heparinized blood collected in these tubes correlated poorly (r = 0.04 to 4 = 0.25) with that of blood samples from the same patients collected in plastic tubes. Most of the evacuated tube APTT were shorter than that of blood collected in plastic or siliconised glass tubes, but the results were unpredictable and varied from tube to tube and from batch to batch. This effect on heparin is apparently due to an unidentified substances which is eluted from the rubber stoppers of the tubes. Heparin control according to the APTT blood collected in these evacuated tubes is hazardous.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7462439      PMCID: PMC1146412          DOI: 10.1136/jcp.34.1.63

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  Spuriously low plasma propranolol concentrations resulting from blood collection methods.

Authors:  R H Cotham; D Shand
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

2.  Letter: Reduced binding of quinidine in plasma from Vacutainers.

Authors:  D Fremstad; K Bergerud
Journal:  Clin Pharmacol Ther       Date:  1976-07       Impact factor: 6.875

3.  Plasma protein binding of drugs as influenced by blood collection methods.

Authors:  D Fremstad; K Bergerud
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976

4.  Comparative evaluation of a partial thromboplastin reagent containing a non-settling, particulate activator.

Authors:  A L Babson; S R Babson
Journal:  Am J Clin Pathol       Date:  1974-12       Impact factor: 2.493

5.  Sensitivity of the activated partial thromboplastin time to heparin: effect of anticoagulant used for sample collection.

Authors:  H B Soloway; S P Cox; J V Donahoo
Journal:  Am J Clin Pathol       Date:  1973-05       Impact factor: 2.493

6.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.

Authors:  D Basu; A Gallus; J Hirsh; J Cade
Journal:  N Engl J Med       Date:  1972-08-17       Impact factor: 91.245

7.  Efficacy and toxicity of heparin in relation to age and sex.

Authors:  H Jick; D Slone; I T Borda; S Shapiro
Journal:  N Engl J Med       Date:  1968-08-08       Impact factor: 91.245

8.  Inhibitor of drug-protein binding in "Vacutainers".

Authors:  K M Piafsky; O Borga
Journal:  Lancet       Date:  1976-10-30       Impact factor: 79.321

9.  Heparin therapy in thromboembolic disease.

Authors:  R J Kernohan; C Todd
Journal:  Lancet       Date:  1966-03-19       Impact factor: 79.321

10.  Control of heparin therapy.

Authors:  W R Pitney; J E Pettit; L Armstrong
Journal:  Br Med J       Date:  1970-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.